<DOC>
	<DOCNO>NCT01455220</DOCNO>
	<brief_summary>The purpose study determine sexual dysfunction symptom quality life measure patient Multiple Sclerosis may improve patient prescribed Tysabri .</brief_summary>
	<brief_title>The Effect Natalizumab ( Tysabri ) Sexual Dysfunction Multiple Sclerosis</brief_title>
	<detailed_description>Patients naive Tysabri baseline study sexual dysfunction , fatigue , quality life measure measure use scaled questionnaire .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>1 . Must give write informed consent provide authorization require local law ( ex . Protected Health Information , PHI ) 2 . Minimum baseline score 15 primary sexual dysfunction subscale MSISQ19 ( question 12,16,17,18,19 ) 3 . Men Women 18 60 year age 4 . Must EDSS less equal 5.5 baseline 5 . Must able walk least 100m without assistive device 6 . Must document diagnosis relapse remit form MS define revise McDonald Committee criterion ( Polman et al.,2005 ) 7 . Must recent MRI ( within 1 year baseline ) 8 . Must satisfy locally approve therapeutic indication TYSABRI 9 . Must stable disability least 30 day prior enrollment study 10 . Must Natalizumab naïve 11 . Must stable symptomatic management disease , least 30 day prior enrollment study 12 . Must stable regimen symptomatic medication Multiple Sclerosis especially could interfere sexual function ( specifically anticholinergic , antihypertensive , etc . ) least 30 day prior enrollment . 13 . Must consider Investigator free sign symptom suggestive PML base medical history , physical examination , laboratory testing . 14 . Must willing discontinue remain free concomitant immunosuppressive immunomodulatory treatment ( include IFN GA ) treat Natalizumab study 1 . Must give write informed consent provide authorization require local law ( ex . Protected Health Information , PHI ) 2 . Minimum baseline score 15 primary sexual dysfunction subscale MSISQ19 ( question 12,16,17,18,19 ) 3 . Men Women 18 60 year age 4 . Must EDSS less equal 5.5 baseline 5 . Must able walk least 100m without assistive device 6 . Must document diagnosis relapse remit form MS define revise McDonald Committee criterion ( Polman et al.,2005 ) 7 . Must recent MRI ( within 1 year baseline ) 8 . Must satisfy locally approve therapeutic indication TYSABRI 9 . Must stable disability least 30 day prior enrollment study 10 . Must Natalizumab naïve 11 . Must stable symptomatic management disease , least 30 day prior enrollment study 12 . Must stable regimen symptomatic medication Multiple Sclerosis especially could interfere sexual function ( specifically anticholinergic , antihypertensive , etc . ) least 30 day prior enrollment . 13 . Must consider Investigator free sign symptom suggestive PML base medical history , physical examination , laboratory testing . 14 . Must willing discontinue remain free concomitant immunosuppressive immunomodulatory treatment ( include IFN GA ) treat Natalizumab study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Sexual Dysfunction</keyword>
	<keyword>Quality Life</keyword>
</DOC>